About the US-Israel Biotech Council

The worldwide biotechnology industry, facing decreasing capital resources and increasing R&D expenditures, is turning to strategic alliances, i.e., joint R&D, technology patent licenses and mergers, as its principal vehicle for growth.

The US- Israel Biotech Council (USIBC) is a nonprofit organization dedicated to promoting strategic alliances between growing North American and Israeli Life Sciences industries, through networking, information exchange, and public policy initiatives.

Networking

Networking between North American and Israeli industry leaders, investors, and researchers is a key priority of the Council. The Council participates in major industry trade shows throughout North America, representing Israeli companies, and promoting binational biotech start-up ventures. In addition the Council cultivates relationships with other biotech associations such as: the Bio Industry Organization, the Maryland Bioscience Alliance and the New York Biotech Association.

Information Exchange

Another priority of the Council is to facilitate binational information exchange, in written or computer readable form, on licensing, joint ventures and investment opportunities.

Using Internet technology, the Council's Web Site serves as an electronic forum and bulletin board for specific topics, updates and recently issued patents, and technology licensing opportunities.

Public Policy/ Government Affairs

The Council's third priority is to advocate and support binational governmental initiatives. These initiatives include the facilitation of funding and support for commercial biotechnology ventures, initiation of trade missions and the establishment of relationships with Chambers of Commerce and nonprofit organizations.

Council Biopartnering Activities:

ALLIANCE: a forum where biotech industry professionals from Israel and North America meet to explore business partnering and technology licensing opportunities.

ALLIANCE '96 ( at BIO '96): Over 170 participants attended a two-day biopartnering program at the annual meeting of the Bio Industry Organization (BIO '96), Philadelphia. The highlight of the ALLIANCE '96 was the "Matchmaking Program" comprised of one-on-one meetings. More then 164 separate meetings were prearranged for 32 licensing directors of North American companies and 24 Israeli representatives. US participants included companies such as Johnson & Johnson, Smith Kline Beecham, Bristol Myers, Bayer, Glaxo-Wellcome and Zeneca.

The 20 ongoing collaboration and interaction of the partners that met at matchmaking program and the excellent feedback of both Israeli and the North American participants encouraged us to continue and plan future biopartnering programs.

In addition to the North American partners, a delegation of 15 Egyptian Biotech companies participated in the program and in the Israel-Egypt Partnering Luncheon sponsored by the USIBC and the NIH- Fogarty Center and hosted by the Philadelphia-Israel Chamber of Commerce.

ALLIANCE '95 (at BioEast 95): Over 130 biotech industry professionals, including representatives from 24 leading Israeli biotech companies and university technology transfer groups participated in the one-day program. ALLIANCE '95 was the first major partnership meeting held as part of BioEast '95 conference in Washington, DC The successful outcome of Three major joint ventures that were established as a result of this conference, prove the need to continue these activities as annual partnering meetings.

World Wide Web/Internet:

To enhance communication among its members and to promote the Council's activities, the USIBC has established a World Wide Web home page ( http:// www.usibc.org). This site includes a directory of Israeli technology available for licensing, a list of Council members, and a schedule of upcoming events. Upon appropriate funding, the Council will explore the possibility of developing an on-line matchmaking program on the Internet, which will assist our members in their partnering efforts.

The Benefits of Annual Sponsorship:

By becoming an annual sponsor and member of the USIBC you will be eligible to receive the following benefits:

• Network with the top US biotech and pharmaceutical CEO's and licensing directors.
• Take advantage of referral and introduction to potential biotech partners & venture capital
• Learn about binational government funding opportunities
• Participate in ALLIANCE panels and steering committee
• Promote and distribute your business literature at all USIBC events
• Have the name of your organization appears in all USIBC literature
• Receive discounts and group rates for national biotech events
• Assist in building and establishing a presence within the US Biotech Industry

Additional Council Services:

In addition, the Council is able to assist your company with a variety of services provided by third parties at a reduced fee:

• Marketing Services: market research, competitive intelligence, direct marketing & distribution setup.
• Technology Assessment and screening
• Intellectual Property advisory
• Brochure and promotion preparation
• Public Relation
• Medical Education

For annual membership and services, please see our attached fee schedule or contact Eli Bismut

Executive Board:

Haim Hardt,Ph.D, President ----- Director,American Red Cross

Eli Bismut,Eng.,MBA, Director ----- President, Global Alliances

Zelda Wildman, Vice President ----- President, Medworks

Eli Malki,MBA,Vice President ----- Hadasit -Hadassah Hospital

Sheldon Berman, CPA ----- Rosen,Sapperstein,Friedlander

William Malamud,MBA,Treasurer ----- SPC International

Mordechi Soloff,VP Finance -----Partner, Price Waterhouse

Sim Fass,Ph.D. -----President, Bio-Technology General Corp

Active Members:

Haim Aviv, Profesor ----- Chairman,Israel Biotech Steering Committee

Oren Baron,CPA ----- Ernst & Young LLp

Jeffrey Berg,V.C. Coordiantor ----- Health Care Insights

Barry Bogage ----- Maryland-Israel Development Center

Edward M. Chait,Ph.D ----- Intergen Company

Jonathan Cohen (founder) ----- Wigman, Cohen, Leitner & Myers, P.C.

Claude Cohen, Ph.D -----Synergix-Drug Design Ltd

Ilan Cohen ----- Reinhold, Cohen, & Partners

Zvi Er-el,Ph.D ----- ClinTrials Research-Israel

Neal Farber,Ph.D. ----- Cubic Pharmaceutical

Pnina Fishman.Profesor ----- Mor Research & Application

Scott Freedman,Ph.D. ----- Centeon Inc.

David Jonas ----- Baxter Healthcare Corp.

Peter Kash ----- Paramount Capital, Inc.

Gary A. King,Ph.D. ----- Bristol-Myers Squibb Company

Avinoam Kowarski,M.D. ----- President, Kay Laboratories

Nathan Low ----- Sunrise Financial Group

Orgad Laub, Profesor ----- Weizmann Institute of Science

Scott E. Mackler -----Marketing Director, Clestra, Cleanroom

Jeff Marcus --------Morrison & Foerster LLP

Ohad Murani ----- Israeli-Economic Minister,Israeli -Embassy.

Janis Plostnieks,Ph.D. ----- Johnson & Johnson

Gad Riesenfeld,Ph.D. ----- Pharmos Corporation

Heschi Rotmensch,Ph.D. ----- Cato Research Israel

David Rubin ----- Economic Mission

Jacques R. Rubin -----Chairman, Bio Science-Contrct Production

Arnold Rubin,Ph.D. ----- Ciba-Geigy Corporation

Ben-Zion Rubinfeld,Ph.D. ----- Ramot-Tel Aviv University

Joseph Schlessinger, Profesor ----- Chairman,Pharmacology Dep. NYU

Joni Catalano-Sherman,Ph.D. ----- Yissum-Hebrew University

Haim Simonovitch,Ph.D. ----- Teva Pharmaceutical-Israel

Howard Sterling ----- The Sterling Group

Eyal Talor, Ph.D. ----- Cell-Sci Corp.

Lawrence Tamarkin,Ph.D.-----President, CYTImmune Sciences,Inc.

For more information call or mail to: USIBC, 1628 Martha Terrace, Rockville, MD 20852.

Tel: (301) 468-2915, Fax: (301) 468-2915, E-mail: [email protected]